CD19/22 bispecific CAR-T cells (ganlee)

N/A

Report date: 2022/03/03 10:22:05

Base Information

Drug NameCD19/22 bispecific CAR-T cells (ganlee)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGan & Lee Pharmaceuticals Jiangsu Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGan & Lee Pharmaceuticals Jiangsu Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A